On 28 August 2026, Samsung Bioepis announced the initiation of a Phase 1 clinical trial for SB35, biosimilar to Eli Lilly’s Taltz® (ixekizumab). The trial has an estimated primary completion date of June 2027 and will compare the pharmacokinetics, safety, tolerability, and immunogenicity of SB35 to Taltz® in healthy participants.
The development of an ixekizumab biosimilar by Samsung Bioepis was first reported in November 2025 and was confirmed by Samsung Epis Holdings in January 2026.
Other ixekizumab biosimilars under early development include Celltrion’s CT-P52 (first announced in January 2026; confirmed in February 2026) and Alvotech’s AVT28 (confirmed in February 2026).